Cancer & Metabolism is a distinguished open-access journal published by BMC, dedicated to advancing the understanding of the complex interactions between cancer biology and metabolic processes. Since its inception in 2013, it has provided a platform for researchers, clinicians, and students to disseminate groundbreaking research and innovative findings within the fields of oncology and metabolism. The journal, identified by its E-ISSN 2049-3002, is recognized for contributing valuable insights into metabolic alterations that influence cancer progression, treatment responses, and overall patient outcomes. With a firm commitment to open access, Cancer & Metabolism ensures that research is freely available to the global scientific community, fostering collaboration and accelerating discoveries that can lead to improved therapeutic strategies. As a vital resource in cancer research, this journal appeals to a broad audience, including researchers looking to share their latest findings, professionals seeking to stay informed on cutting-edge developments, and students eager to delve into the relationship between metabolism and cancer.

Journal of Clinical Lipidology, published by Elsevier Science Inc, is a leading platform dedicated to advancing the understanding of lipidology and its impact on cardiovascular health. With an ISSN of 1933-2874 and E-ISSN 1876-4789, this esteemed journal boasts a remarkable Q1 ranking in key medical categories, including Cardiology and Cardiovascular Medicine, Internal Medicine, and Nutrition and Dietetics, solidifying its position as a vital resource for the latest research and clinical practices. This journal not only serves as a repository for groundbreaking studies but also provides insights into complex interactions between lipid metabolism and chronic diseases, including diabetes and obesity. Researchers, practitioners, and students will find a wealth of carefully vetted articles that drive innovation and improve patient outcomes in lipid management. Although it does not currently offer open access, the Journal of Clinical Lipidology ensures high visibility through rigorous peer review and a commitment to quality, making it an essential read for anyone invested in the future of lipidology.

Chemistry and Physics of Lipids is a prestigious and influential journal dedicated to advancing the understanding of lipid chemistry and biophysics. Published by Elsevier Ireland Ltd, it serves as a vital resource for researchers and professionals in the fields of biochemistry, cell biology, and molecular biology. The journal has a strong standing within the academic community, as reflected in its 2023 Scopus rankings, where it places in the 82nd percentile for organic chemistry and maintains significant positions in various biochemistry subfields. Spanning from 1966 to 2024, it fosters a comprehensive discourse on lipid-related research and innovation. As a renowned publication in the Q2 and Q3 quartiles across several categories, it supports the dissemination of high-quality research aimed at elucidating lipid functions and their implications in health and disease. Researchers and students alike will find this journal invaluable for staying updated with the latest developments and trends in lipid research.

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS is a distinguished peer-reviewed journal dedicated to advancing the understanding of the biological roles of prostaglandins, leukotrienes, and essential fatty acids in human health and disease. Published by Elsevier Science Ltd, this journal has been at the forefront of research since its inception in 1988 and continues to serve as a vital resource for researchers, clinicians, and students involved in the fields of biochemistry and cell biology. With its impact factor reflecting a solid academic presence—ranking Q3 in Cell Biology and Q2 in Clinical Biochemistry in 2023—this journal is recognized for its quality contributions, particularly in uncovering the biochemical pathways and clinical implications of these lipid mediators. Though not an open-access journal, it provides various access options to ensure the dissemination of critical findings. As the field evolves, PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS remains a pivotal platform for the exploration and discussion of new methodologies, therapeutic avenues, and biological discoveries that impact patient care and the foundational sciences.

ANNALS OF NUTRITION AND METABOLISM is a prestigious academic journal dedicated to advancing the fields of nutrition and metabolism, published by KARGER, a renowned publisher known for its commitment to high-quality research dissemination. Founded in 1959, this journal has established itself as a crucial resource for researchers and practitioners alike, spanning an extensive range of topics that highlight the interplay between diet, health, and disease. Currently seated in Q2 categorically both in Medicine (Miscellaneous) and Nutrition and Dietetics, the journal ranks impressively within the Scopus metrics, showcasing its relevance and impact—positioned at the 80th percentile in Medicine and the 71st percentile in Nutrition. Though not open access, the journal ensures broad accessibility through various academic databases. By focusing on innovative research findings and clinical insights, the ANNALS OF NUTRITION AND METABOLISM aims to foster a deeper understanding of nutritional science, making it an indispensable platform for academics, healthcare professionals, and students alike to enhance their knowledge and contribute to ongoing discussions in this vital field.

PROSTAGLANDINS & OTHER LIPID MEDIATORS, published by Elsevier Science Inc, is a leading journal dedicated to the advancements in the field of lipid mediators, with a specific focus on prostaglandins and other bioactive lipids. This journal, indexed under ISSN 1098-8823 and E-ISSN 2212-196X, serves as a crucial platform for researchers and professionals to disseminate significant findings that span multiple disciplines, including Biochemistry, Cell Biology, Pharmacology, and Physiology. In the 2023 category quartiles, it has achieved commendable positions such as Q2 in Biochemistry and Q2 in Physiology, underscoring its importance and influence in these domains. Although it is not an open-access journal, it provides robust access options, enhancing the visibility of vital research. With its establishment in 1996, the journal continues its commitment to fostering innovative research until 2024, making it an essential resource for those involved in the dynamic realms of lipid biology and medical research.

Molecular Therapy Nucleic Acids is a premier open-access journal published by CELL PRESS, dedicated to advancing the field of molecular medicine through the innovative application of nucleic acid-based therapies. Since its inception in 2012, this journal has become an essential resource for researchers and professionals in drug discovery and molecular medicine, reflected in its status as a Q1 journal in both categories for 2023. With a notable impact factor and high rankings in Scopus, including #8 out of 157 in Drug Discovery and #16 out of 178 in Molecular Medicine, it serves to disseminate groundbreaking research and foster collaborations among scientists worldwide. The journal's comprehensive scope encompasses a wide variety of topics, including gene therapy, RNA interference, and CRISPR technology, ensuring that it remains at the forefront of scientific excellence. With open access availability, Molecular Therapy Nucleic Acids actively promotes the widespread dissemination of knowledge, making its crucial insights accessible to students, researchers, and industry professionals alike.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, published by Lippincott Williams & Wilkins, is a leading journal in the field of cardiovascular medicine, dedicated to the advancement of research surrounding arterial diseases, thrombosis, and vascular biology. With an impressive impact factor indicative of its reach and influence, this journal occupies a prominent position in the Q1 category of cardiology, ranking 13th out of 387 in its field according to Scopus, placing it within the top 96th percentile among cardiovascular research journals. Since its inception in 1990, ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY has been pivotal in disseminating cutting-edge research that drives innovation and education in cardiovascular health. Although it does not operate under an open access model, the journal is a vital resource for researchers, clinicians, and students looking for high-quality, peer-reviewed articles that contribute to the understanding and treatment of cardiovascular and vascular disorders. Its commitment to rigorous scientific standards and its focus on impactful findings make it an essential publication for anyone dedicated to the field.

JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to the study of bioenergetics and biomembranes, covering essential topics such as cellular energy transformation and membrane dynamics. Since its inception in 1976, the journal has developed a robust reputation within the scientific community, currently holding a Q3 ranking in Cell Biology and a Q2 ranking in Physiology for 2023. Boasting a prestigious Scopus Rank in both Biochemistry and Physiology, it serves as a crucial platform for disseminating pioneering research findings. With its commitment to quality and innovation, the journal plays a significant role in advancing our understanding of the fundamental processes that underlie life at the cellular level. Although it does not offer open access options, the journal remains accessible through universities and research institutions, ensuring that vital research is widely shared among scholars, professionals, and students alike. The JOURNAL OF BIOENERGETICS AND BIOMEMBRANES is essential for anyone seeking to contribute to or stay informed about developments in this dynamic field.

PPAR Research, an esteemed journal published by HINDAWI LTD, specializes in the rapidly evolving fields of drug discovery and pharmacology, contributing significantly to the body of research surrounding peroxisome proliferator-activated receptors (PPARs) and their roles in various biochemical processes. With an open access policy implemented since 2006, the journal ensures that its high-quality content is readily available, promoting widespread dissemination of knowledge. Currently ranked in the Q2 category for both Drug Discovery and Medical Pharmacology, it boasts a respectable position within the scientific community, evidenced by its Scopus rankings. PPAR Research serves as an essential resource for researchers, professionals, and students looking to advance their understanding of PPAR biology and its implications in therapeutic development. The journal's commitment to excellence and accessibility makes it a key player in supporting innovative research and critical discussions in the life sciences.